Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin
- PMID: 19584280
- DOI: 10.1158/0008-5472.CAN-09-0299
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin
Abstract
The mammalian target of rapamycin (mTOR) is centrally involved in cell growth, metabolism, and angiogenesis. While showing clinical efficacy in a subset of tumors, rapamycin and rapalogs are specific and allosteric inhibitors of mTOR complex 1 (mTORC1), but they do not directly inhibit mTOR complex 2 (mTORC2), an emerging player in cancer. Here, we report chemical structure and biological characterization of three pyrazolopyrimidine ATP-competitive mTOR inhibitors, WAY-600, WYE-687, and WYE-354 (IC(50), 5-9 nmol/L), with significant selectivity over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold). Unlike the rapalogs, these inhibitors acutely blocked substrate phosphorylation by mTORC1 and mTORC2 in vitro and in cells in response to growth factor, amino acids, and hyperactive PI3K/AKT. Unlike the inhibitors of PI3K or dual-pan PI3K/mTOR, cellular inhibition of P-S6K1(T389) and P-AKT(S473) by the pyrazolopyrimidines occurred at significantly lower inhibitor concentrations than those of P-AKT(T308) (PI3K-PDK1 readout), showing mTOR selectivity in cellular setting. mTOR kinase inhibitors reduced AKT downstream function and inhibited proliferation of diverse cancer cell lines. These effects correlated with a strong G(1) cell cycle arrest in both the rapamycin-sensitive and rapamycin-resistant cells, selective induction of apoptosis, repression of global protein synthesis, and down-regulation of angiogenic factors. When injected into tumor-bearing mice, WYE-354 inhibited mTORC1 and mTORC2 and displayed robust antitumor activity in PTEN-null tumors. Together, our results highlight mechanistic differentiation between rapalogs and mTOR kinase inhibitors in targeting cancer cell growth and survival and provide support for clinical development of mTOR kinase inhibitors as new cancer therapy.
Similar articles
-
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.Cancer Res. 2010 Jan 15;70(2):621-31. doi: 10.1158/0008-5472.CAN-09-2340. Epub 2010 Jan 12. Cancer Res. 2010. PMID: 20068177
-
Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor.Methods Mol Biol. 2012;821:15-28. doi: 10.1007/978-1-61779-430-8_2. Methods Mol Biol. 2012. PMID: 22125057
-
Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.Biochem Pharmacol. 2012 May 1;83(9):1183-94. doi: 10.1016/j.bcp.2012.01.019. Epub 2012 Jan 26. Biochem Pharmacol. 2012. PMID: 22305748
-
New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64. Curr Top Microbiol Immunol. 2010. PMID: 20549474 Review.
-
Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.Curr Opin Drug Discov Devel. 2010 Jul;13(4):428-40. Curr Opin Drug Discov Devel. 2010. PMID: 20597028 Review.
Cited by
-
Interaction of polyamines and mTOR signaling in the synthesis of antizyme (AZ).Cell Signal. 2015 Sep;27(9):1850-9. doi: 10.1016/j.cellsig.2015.06.002. Epub 2015 Jun 17. Cell Signal. 2015. PMID: 26093026 Free PMC article.
-
Amino acids and mTORC1: from lysosomes to disease.Trends Mol Med. 2012 Sep;18(9):524-33. doi: 10.1016/j.molmed.2012.05.007. Epub 2012 Jun 28. Trends Mol Med. 2012. PMID: 22749019 Free PMC article. Review.
-
Novel drugs that target the metabolic reprogramming in renal cell cancer.Cancer Metab. 2016 Jul 13;4:14. doi: 10.1186/s40170-016-0154-8. eCollection 2016. Cancer Metab. 2016. PMID: 27418963 Free PMC article. Review.
-
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.Target Oncol. 2011 Jun;6(2):69-94. doi: 10.1007/s11523-011-0178-5. Epub 2011 May 4. Target Oncol. 2011. PMID: 21541789 Review.
-
Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.Cell Oncol (Dordr). 2018 Aug;41(4):409-426. doi: 10.1007/s13402-018-0380-x. Epub 2018 May 22. Cell Oncol (Dordr). 2018. PMID: 29790111
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous